Literature DB >> 21977925

Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia.

Gabriela Meléndez-Ramírez1, Oscar Pérez-Méndez, Cristhel López-Osorio, Jorge Kuri-Alfaro, Nilda Espinola-Zavaleta.   

Abstract

BACKGROUND: Hyperuricemia has been associated with an increased risk of endothelial dysfunction (ED), cardiovascular and renal disease. The role of uric acid (UA) on vascular damage is still controversial because previous studies have included patients with other risk factor for ED.
OBJECTIVE: To determine if the treatment with allopurinol improved endothelial function in hyperuricemic patients without other risk factors for ED.
MATERIAL AND METHODS: In order to gain more insight about the contribution of UA to the ED, we screened 369 apparently healthy male individuals for UA in a period of 9 months. Only 9 patients fulfill the inclusion criteria: UA plasma levels > 7 mg/dL without other risk factors for ED such as hypercholesterolemia, obesity, diabetes and hypertension.
RESULTS: Endothelial function, assessed by flow mediated dilatation (FMD) in the brachial artery improved significantly after 30 days of allopurinol treatment (9.6% [6.3-13.3%] vs. 13.7% [11-14.7%], p = 0.036), concomitantly with a decrease of about 45% in the uric acid plasma levels. Other parameters were not modified by allopurinol treatment. Any No significant correlation was found (r = -0.367, p = 0.33) between the ΔUA plasma levels (UA after treatment - UA in basal conditions) and ΔFMD (FMD after treatment - FMD in basal conditions).
CONCLUSIONS: These results strongly suggest that allopurinol improves flow-mediated vasodilation regardless of uric acid plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21977925     DOI: 10.3109/07435800.2011.566235

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  16 in total

1.  Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Niteesh Choudhry; Jun Liu; Robert J Glynn; Daniel H Solomon
Journal:  Am J Med       Date:  2015-02-03       Impact factor: 4.965

2.  Hyperuricemia is Associated with Increased Apo AI Fractional Catabolic Rates and Dysfunctional HDL in New Zealand Rabbits.

Authors:  Miriam Martínez-Ramírez; Cristóbal Flores-Castillo; L Gabriela Sánchez-Lozada; Rocío Bautista-Pérez; Elizabeth Carreón-Torres; José Manuel Fragoso; José Manuel Rodriguez-Pérez; Fernando E García-Arroyo; Victoria López-Olmos; María Luna-Luna; Gilberto Vargas-Alarcón; Martha Franco; Oscar Pérez-Méndez
Journal:  Lipids       Date:  2017-09-22       Impact factor: 1.880

3.  Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.

Authors:  Seoyoung C Kim; Tuhina Neogi; Eun Ha Kang; Jun Liu; Rishi J Desai; MaryAnn Zhang; Daniel H Solomon
Journal:  J Am Coll Cardiol       Date:  2018-03-06       Impact factor: 24.094

4.  Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.

Authors:  Ciaran J McMullan; Lea Borgi; Naomi Fisher; Gary Curhan; John Forman
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-20       Impact factor: 8.237

5.  Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Lea Borgi; Ciaran McMullan; Ann Wohlhueter; Gary C Curhan; Naomi D Fisher; John P Forman
Journal:  Hypertension       Date:  2016-12-27       Impact factor: 10.190

6.  Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.

Authors:  Svetlana Krasnokutsky; Aaron Garza Romero; Daisy Bang; Virginia C Pike; Binita Shah; Talia F Igel; Irina Dektiarev; Yu Guo; Judy Zhong; Stuart D Katz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2018-02-15       Impact factor: 2.980

7.  The effects of topiroxostat on vascular function in patients with hyperuricemia.

Authors:  Shingo Higa; Daisuke Shima; Naoko Tomitani; Yoko Fujimoto; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-26       Impact factor: 3.738

8.  Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study.

Authors:  Mara A McAdams-DeMarco; Andrew Law; Janet W Maynard; Josef Coresh; Alan N Baer
Journal:  BMC Musculoskelet Disord       Date:  2013-12-11       Impact factor: 2.362

9.  The associations of uric acid, cardiovascular and all-cause mortality in peritoneal dialysis patients.

Authors:  Jie Dong; Qing-Feng Han; Tong-Ying Zhu; Ye-Ping Ren; Jiang-Hua Chen; Hui-Ping Zhao; Meng-Hua Chen; Rong Xu; Yue Wang; Chuan-Ming Hao; Rui Zhang; Xiao-Hui Zhang; Mei Wang; Na Tian; Hai-Yan Wang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 10.  Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis.

Authors:  L E Clarson; P Chandratre; S L Hider; J Belcher; C Heneghan; E Roddy; C D Mallen
Journal:  Eur J Prev Cardiol       Date:  2013-11-26       Impact factor: 7.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.